- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Antigenicity.
Displaying page 1 of 1.
EudraCT Number: 2004-003799-13 | Sponsor Protocol Number: 25632 | Start Date*: 2005-02-03 | |||||||||||
Sponsor Name:Serono International SA | |||||||||||||
Full Title: A multicentre, single arm, open-label, phase IIIb study to evaluate the safety and antigenicity of Rebif® (IFN-beta-1a) in subjects with relapsing forms of multiple sclerosis. | |||||||||||||
Medical condition: Relapsing form of MS ; diagnosis of MS is in accordance with the McDonald criteria | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) LT (Completed) IE (Completed) DK (Completed) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003993-16 | Sponsor Protocol Number: IM-T-hPAM4-02 | Start Date*: 2009-04-03 | ||||||||||||||||
Sponsor Name:Immunomedics, Inc. | ||||||||||||||||||
Full Title: A Phase Ib/II Study of Fractionated 90-Y-hPAM4 Plus Gemcitabine in Patients with Previously Untreated Advanced Pancreatic Cancer | ||||||||||||||||||
Medical condition: This is a phase Ib, open-label, dose exploration study of 90-Y-hPAM4 administered as one or more treatment cycles of fractionated radioimmunotherapy in combination with radiosensitizing gemcitabine... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001857-29 | Sponsor Protocol Number: V130_14 | Start Date*: 2019-03-13 | |||||||||||
Sponsor Name:Seqirus UK Limited | |||||||||||||
Full Title: A Phase III, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus' Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to... | |||||||||||||
Medical condition: Prophylaxis of influenza virus infection | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) EE (Completed) CZ (Completed) LV (Completed) PL (Completed) Outside EU/EEA RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002678-21 | Sponsor Protocol Number: APO-Peg-03 | Start Date*: 2012-01-10 | |||||||||||
Sponsor Name:Apotex Inc | |||||||||||||
Full Title: A PHASE III, RANDOMIZED, ACTIVE CONTROLLED, ASSESSORBLINDED STUDY OF SAFETY AND EFFICACY OF PEGYLATED APOFILGRASTIM VERSUS US AND EU LICENSED NEULASTA® IN SUBJECTS WITH STAGE IIA, IIB OR IIIA BREA... | |||||||||||||
Medical condition: Febrile neutropenia in breast cancer patients undergoing TAC chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) BG (Completed) GR (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000933-18 | Sponsor Protocol Number: HLSC-UCD-02 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Unicyte AG | |||||||||||||
Full Title: An Open-label, Non-controlled, Multi-center, Phase 2 Study to Assess the Efficacy and Safety of Allogeneic Human Liver Stem Cells (HLSCs) in the Treatment of Pediatric Patients with Early-onset Ure... | |||||||||||||
Medical condition: Urea cycle disorders | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004721-24 | Sponsor Protocol Number: QHD00014 | Start Date*: 2020-09-07 | |||||||||||
Sponsor Name:Sanofi Pasteur Inc. | |||||||||||||
Full Title: Efficacy, Immunogenicity, and Safety of High-Dose Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months through 35 Months of Age | |||||||||||||
Medical condition: Prevention of influenza infection in children 6 months through 35 months of age | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001937-40 | Sponsor Protocol Number: EORTC 16032-18031 | Start Date*: 2005-05-19 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer | |||||||||||||
Full Title: Randomized, open phase II study of immunization with the recombinant MAGE-3 protein combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanoma | |||||||||||||
Medical condition: Unresectable and progressive metastatic cutaneous melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
